Chagas Disease
Vaccines Forecast
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, remains one of the world's most under-resourced neglected tropical diseases: an estimated 6-7 million people carry the parasite worldwide, around 10,000 die from its chronic complications each year, and still no vaccine exists. This comprehensive commercial opportunity assessment covers T. cruzi vaccine profiles across LATAM, US and EU markets, modelling two therapeutic (TX) profiles in determinate and indeterminate populations, alongside a prophylactic (PX) profile. It draws on VacZine Analytics' long-standing expertise in Endemic/Diarrhoeal diseases.
- Format
- Executive presentation + 1 Excel model
- Coverage
- LATAM, US & EU
- Vaccine profiles
- 2x TX (determinate/indeterminate) + 1x PX
- Forecast horizon
- To 2035
- Approach
- Value/volume demand model
- Edition
- 2020
- Availability
- Syndicated / bespoke
infection worldwide
Chagas disease
determinate (chronic) disease
2 antiparasitic drugs only
A textbook neglected tropical disease, now spreading well beyond Latin America
Chagas disease sits at the heart of VacZine Analytics' long-standing expertise in Endemic/Diarrhoeal diseases. This review sets out the parasitology, transmission routes, natural history and global burden of the disease before turning to the treatment landscape and vaccine pipeline.
Pathogen overview - Trypanosoma cruzi (Chagas disease)
Chagas disease, also known as American trypanosomiasis, is caused by the protozoan parasite Trypanosoma cruzi (T. cruzi). The parasite is classically transmitted to humans through contact with the faeces of infected triatomine bugs, colloquially known as "kissing bugs" because they typically bite around the mouth or eyes of a sleeping host at night before defecating near the bite site, allowing the parasite to enter through broken skin or mucous membranes. T. cruzi can also be transmitted congenitally from mother to child, through blood transfusion and organ transplantation, and, in a route of growing recognition across Latin America, through oral ingestion of food or drink contaminated with triatomine faeces or the parasite itself, which has driven a number of documented outbreak clusters in recent years.
Following acute infection, most individuals enter a lifelong indeterminate phase: they carry the parasite and test seropositive, but show no clinical symptoms, and this phase can persist for decades without detection. However, an estimated 30-40% of infected people eventually progress to the determinate, or chronic, phase, in which the disease manifests as serious cardiac disease (Chagas cardiomyopathy, arrhythmias, heart failure and sudden cardiac death) and, less commonly, gastrointestinal disease (megaoesophagus and megacolon). It is this long, silent latency, followed by a substantial minority converting to severe and often fatal disease, that makes Chagas such a distinctive vaccine target, and one where both therapeutic and prophylactic approaches are scientifically justified.
Historic estimates, including this report's own 2020-era baseline, put the infected population at around 10 million people, with roughly 99% resident in Latin America. Current WHO and PAHO-aligned estimates are more conservative on headline prevalence, generally citing 6 to 7 million people infected worldwide (with regional estimates for the endemic Americas running somewhat higher, around 7.5 million, against more than 100 million people at risk), alongside around 30,000 new cases and approximately 10,000 deaths a year attributable to chronic Chagas disease, and an estimated annual economic cost in the region of $500 million and around 770,000 disability-adjusted life years (DALYs) lost. Whichever headline figure is used, the more consequential change since 2020 is geographic: sustained migration from Latin America has moved substantial, under-diagnosed T. cruzi-infected populations into the United States and Europe, meaning Chagas disease is now firmly recognised as a health issue for high-income, non-endemic health systems as well as for its traditional endemic base, with congenital transmission in non-endemic countries a particular and growing concern for maternal and paediatric screening programmes.
Two ageing drugs, a chronically underfunded field, and an early academic pipeline
Chagas disease is a textbook case of neglected tropical disease underinvestment. Antiparasitic treatment has barely changed in decades, and despite the scale of the burden, T. cruzi vaccine research has attracted a fraction of the funding directed at comparable disease areas, leaving the pipeline dominated by early-stage, largely academic and philanthropically-funded programmes.
-
BenznidazoleApproved antiparasiticFirst-line antiparasitic therapy One of only two approved drugs worldwide
Highly effective in the acute phase and in congenital infection, with cure rates approaching 100% when given early, but efficacy falls substantially in the chronic phase, and treatment courses are frequently limited by adverse reactions, including rash, peripheral neuropathy and, rarely, severe haematological effects, that drive poor tolerability and incomplete courses. -
NifurtimoxApproved antiparasiticSecond approved antiparasitic therapy Alternative or second-line option
The only other antiparasitic drug approved for Chagas disease, sharing benznidazole's core limitations: reduced efficacy the longer a person has been infected, a high rate of adverse reactions, particularly in older patients, and a history of supply shortages that has constrained access even where treatment is indicated. -
Baylor College of Medicine / Texas Children's Hospital Center for Vaccine Development / Sabin Vaccine InstituteAcademic, early clinical-stageTc24-C4 and TSA1-C4 recombinant antigen candidates Therapeutic (TX) vaccine approach
Long-running academic development of recombinant Tc24 and TSA-1 antigens, designed as a therapeutic vaccine to activate Tc1 CD8-positive T-cell responses against T. cruzi-infected cells and slow or halt progression to chronic cardiomyopathy. A February 2026 epitope-mapping study confirmed that both candidate antigens are recognised by antibodies from T. cruzi-infected patients in Argentina, Honduras and Mexico, supporting continued advancement of Tc24-C4 and TSA1-C4 toward Phase I human trials, alongside a 2025 randomised field trial demonstrating protective efficacy of a related therapeutic vaccine formulation in naturally infected dogs. -
Academic & philanthropic fundersChronic underfundingThe classic neglected tropical disease funding gap
Despite a disease burden concentrated among some of the poorest communities in the Americas, and increasingly recognised in migrant populations in the US and Europe, T. cruzi vaccine R&D has historically received a small fraction of the funding directed at higher-profile disease areas. The pipeline remains dominated by university and NIH-adjacent research groups rather than well-resourced commercial developers, a funding gap this report states plainly rather than glossing over. -
Global health & academic consortiaSurveillance & literature reviewOngoing epidemiological and outbreak surveillance
Recent systematic reviews of orally-transmitted Chagas disease outbreaks in Latin America, alongside updated Global Burden of Disease Study analyses, continue to refine country-level burden estimates that any future vaccine investment case, including this report's own model, must draw upon.
No T. cruzi vaccine candidate has yet entered formal clinical trials, even as the Tc24-C4 and TSA1-C4 academic programmes move closer to that milestone. This is not a science problem so much as a funding and prioritisation problem: Chagas disease is a genuinely and chronically under-resourced neglected tropical disease, and vaccine investment has lagged its true burden for decades. That gap is precisely what creates the commercial opportunity this report quantifies, across two therapeutic (TX) profiles in determinate and indeterminate populations, and one prophylactic (PX) profile, spanning LATAM, US and EU markets to 2035.
A wide-geography, multi-profile commercial opportunity assessment
This is a genuinely comprehensive report with wide geographic focus, spanning epidemiology, treatment, cost implications and vaccine development history, alongside a full commercial forecast across three regions and three distinct vaccine profiles.
Value/volume demand modelling to 2035 across the three regions carrying the greatest share of diagnosed and undiagnosed T. cruzi infection.
TX vaccine profiles modelled separately in determinate (chronic) and indeterminate populations, reflecting their distinct clinical and commercial dynamics.
Investigation of a prophylactic vaccine profile alongside the therapeutic profiles, reflecting the field's dual TX/PX development approach.
Up-to-date review of the literature on prevalence, transmission and the growing US/EU burden driven by migration.
Review of the benznidazole/nifurtimox treatment landscape, tolerability challenges, and the associated cost implications of chronic disease management.
Full review of Chagas vaccine development to date, including the current early-stage Tc24-C4/TSA1-C4 academic programmes.
A glimpse of the commercial model
The table below shows a partial view of the profile, geography and population framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Vaccine profile | Geography | Target population | Disease phase | Revenue scenario |
|---|---|---|---|---|
| TX Profile 1 | LATAM | Diagnosed, symptomatic | Determinate (chronic) | Modelled |
| TX Profile 2 | US | Diagnosed, asymptomatic | Indeterminate | Modelled |
| PX Profile | EU | At-risk / general population | Pre-infection | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All populations | All phases | $███m |
What you receive
A focused intelligence package combining a detailed executive presentation and a single, fully interactive forecast model, built for organisations evaluating the Chagas disease vaccine opportunity.
- Executive summary presentation - disease background, global burden, treatment landscape and vaccine development history to date
- MS-Excel demand model - value/volume outputs to 2035 for two therapeutic (TX) profiles across determinate and indeterminate populations, plus one prophylactic (PX) profile
- LATAM, US & EU coverage - each region modelled individually and in aggregate
- Treatment landscape review - benznidazole and nifurtimox, tolerability, access and cost implications
- Vaccine pipeline review - Tc24-C4/TSA1-C4 academic candidates and the broader neglected tropical disease funding context
- Up-to-date literature review - epidemiology, migration-driven burden shifts and congenital transmission
Built for organisations evaluating the Chagas disease vaccine opportunity
Most valuable to teams assessing the T. cruzi vaccine market against their own pipeline, BD ambitions, funding strategy or investment thesis.
Vaccine developers
Positioning and commercial feasibility assessment for TX and PX T. cruzi vaccine candidates entering an open, underfunded field.
Corporate strategy & BD
Validate market structure and opportunity sizing across LATAM, US and EU ahead of licensing or partnership discussions.
Investors & analysts
Independent assessment of the commercial case for a genuinely neglected tropical disease vaccine opportunity.
Public health & NTD funders
Evidence base to support philanthropic and public funding decisions in a chronically under-resourced disease area.
Researchers & academia
Comprehensive epidemiology and pipeline landscape for grant applications and Chagas vaccine research planning.
Market access & policy
Pricing benchmarks and access-pathway considerations across LATAM, US and EU health systems.
VacZine Analytics has drawn on its long-standing expertise in Endemic/Diarrhoeal diseases to build this Chagas disease assessment. This is a very comprehensive report with wide geographic focus, covering LATAM, US and EU markets and three distinct vaccine profiles, and it has been well received by clients in the field for the depth of its epidemiological and commercial analysis of a genuinely neglected tropical disease.
This report was last published as the 2020 edition; any refresh would incorporate current WHO/PAHO global burden data, the growing recognition of Chagas disease burden in the US and Europe through migration, and the early-stage Tc24-C4/TSA1-C4 academic vaccine pipeline now moving toward clinical trials. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Chagas disease vaccine analysis, a briefing call is included on request.